Nexalin's Neurostimulation Trial Shows 77.8% Anxiety Response Rate In Brazil; Stock Up
Nexalin Technology (NXL) reported positive eight-week clinical trial results for its non-invasive DIFS neurostimulation in adults with generalized anxiety disorder and comorbid insomnia. Conducted at the University of São Paulo’s Institute of Psychiatry, the study used a 15 mA, 77.5 Hz protocol across 20 40-minute sessions. Nexalin said the end-of-treatment anxiety response rate was 77.8% (HAM-A drop by Session 5 and maintained at follow-up), with no serious adverse events.
Positive clinical readout for Nexalin’s non-invasive DIFS protocol supports commercialization confidence and can re-rate risk for the stock.
Nexalin reported positive eight-week generalized anxiety disorder trial results, including a 77.8% anxiety response rate and no serious adverse events.
Near-term upside bias as traders price in improved probability of commercialization/next trial steps; magnitude likely tempered by microcap liquidity and remaining clinical/commercial uncertainties.
Background
Nexalin is developing non-invasive Deep Intracranial Frequency Stimulation (DIFS) for neuropsychiatric conditions; this report covers an eight-week clinical trial in Brazil for generalized anxiety disorder with comorbid insomnia.
Why it matters
The disclosed efficacy (HAM-A/ HAMD/ PSQI improvements) and safety (no serious adverse events, seizures, or manic/hypomanic switches) are direct catalysts for reassessing Nexalin’s clinical progress and commercialization prospects in Brazil.
Market relevance
A fresh, positive clinical readout with specific efficacy/safety metrics can drive speculative demand and improve perceived probability of next development/commercial steps.
Market effects
Strengthens sentiment toward non-invasive neurostimulation approaches for neuropsychiatric indications, potentially improving read-through for similar platforms.
Brazil trial at University of São Paulo may support local commercialization narratives for non-pharmacological mental-health treatments.
If replicated, efficacy/safety data could influence global investor appetite for DIFS-like frequency-based neuromodulation modalities.
Alternative perspectives
Response/remission rates and score drops may not translate into regulatory-grade endpoints or durable real-world outcomes; follow-up duration is limited.
The article doesn’t provide comparator/control details, sample size, or statistical significance; traders may overreact to headline response rates without those specifics.
Key entities
- companyNexalin Technology, Inc.
Developer of non-invasive DIFS neurostimulation device; reported positive trial outcomes.
- research_siteUniversity of São Paulo (Institute of Psychiatry)
Conducted the trial in Brazil.
- executiveMark White
CEO who characterized results as a major milestone and validated the platform’s differentiated approach.
